Pfizer Inc. $PFE Stake Increased by Mount Vernon Associates Inc. MD

Mount Vernon Associates Inc. MD increased its stake in Pfizer Inc. (NYSE:PFE) by 9.1% in the second quarter, Holdings Channel reports. The institutional investor owned 43,319 shares of the biopharmaceutical company’s stock after acquiring an additional 3,606 shares during the quarter. Mount Vernon Associates Inc. MD’s holdings in Pfizer were worth $1,050,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Brighton Jones LLC increased its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. Vest Financial LLC increased its stake in shares of Pfizer by 73.5% in the first quarter. Vest Financial LLC now owns 47,252 shares of the biopharmaceutical company’s stock worth $1,197,000 after buying an additional 20,018 shares during the last quarter. Signal Advisors Wealth LLC increased its stake in shares of Pfizer by 16.6% in the first quarter. Signal Advisors Wealth LLC now owns 8,826 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 1,258 shares during the last quarter. Finally, Insight Advisors LLC PA bought a new stake in shares of Pfizer in the first quarter worth $215,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.41.

Pfizer Stock Performance

Shares of PFE opened at $27.37 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a market cap of $155.59 billion, a price-to-earnings ratio of 14.56, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a fifty day moving average of $24.67 and a 200-day moving average of $24.14.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.